Suppr超能文献

免疫相关不良事件相关的肾上腺功能不全介导免疫检查点抑制剂在癌症治疗中的疗效。

Immune-Related Adverse Event-Related Adrenal Insufficiency Mediates Immune Checkpoint Inhibitors Efficacy in Cancer Treatment.

作者信息

Zhang Shasha, Wu Jianhua, Zhao Yue, Zhang Jingjing, Zhang Xiaoyun, Wu Chensi, Zhang Zhidong, Guo Zhanjun

机构信息

Department of Immunology and Rheumatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, People's Republic of China.

Animal Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050011, People's Republic of China.

出版信息

Cancer Manag Res. 2024 Mar 14;16:151-161. doi: 10.2147/CMAR.S444916. eCollection 2024.

Abstract

PURPOSE

Immune checkpoint inhibitors (ICIs) have significantly improved the outcomes of patients with cancer; however, these agents may initiate immune-related adverse events (irAEs). Previous studies have demonstrated a robust correlation between disease prognosis and the occurrence of irAEs, specifically skin or endocrine irAEs. Herein, we aimed to evaluate the correlation between irAE-related adrenal insufficiency (AI) and ICI treatment efficacy.

PATIENTS AND METHODS

Patients diagnosed with gastrointestinal, respiratory, head and neck, urological, skin and gynecologic cancers treated with anti-programmed cell death 1 (PD-1)/anti-programmed cell death ligand 1 (PD-L1) antibody as monotherapy or combined therapy (combined with chemotherapy or targeted therapy) were divided into irAE-A (patients with irAE-related AI), irAE-B (patients with other irAEs) and non-irAE groups. Immunotherapy efficacy was assessed based on the disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Survival probabilities were estimated using the Kaplan-Meier method with the log-rank test.

RESULTS

Of the 192 patients enrolled in our study, 17 developed irAE-related AI and 83 developed other irAEs. The DCR of the irAE-A and irAE-B groups were higher than that of the non-irAE group (<0.05). Multiple extended Cox regression analyses showed that irAE status (irAE-A vs non-irAE, =0.008; irAE-B vs non-irAE, =0.020), Eastern Cooperative Oncology Group (ECOG) status (=0.045), tumor-node-metastasis (TNM) stage (=0.000), and treatment line (=0.002) were independent predictors of PFS. Contrarily, irAE status (irAE-A vs non-irAE, =0.009; irAE-B vs non-irAE, =0.013), ECOG status (=0.007), TNM stage (=0.035), treatment line (=0.001) and treatment modality (=0.008) were independent predictors for OS.

CONCLUSION

IrAE-related AI was significantly associated with ICI treatment efficacy in patients with cancer, which could be a potentially predictable marker. Due to the destruction of adrenal tissue by T cells with enhanced activity, AI reflects enhanced T cell activity to some extent.

摘要

目的

免疫检查点抑制剂(ICI)显著改善了癌症患者的预后;然而,这些药物可能引发免疫相关不良事件(irAE)。既往研究表明疾病预后与irAE的发生,特别是皮肤或内分泌irAE之间存在密切关联。在此,我们旨在评估irAE相关肾上腺功能不全(AI)与ICI治疗疗效之间的相关性。

患者与方法

将诊断为胃肠道、呼吸道、头颈部、泌尿系统、皮肤和妇科癌症并接受抗程序性细胞死亡蛋白1(PD-1)/抗程序性细胞死亡配体1(PD-L1)抗体单药治疗或联合治疗(联合化疗或靶向治疗)的患者分为irAE-A组(irAE相关AI患者)、irAE-B组(其他irAE患者)和非irAE组。基于疾病控制率(DCR)、无进展生存期(PFS)和总生存期(OS)评估免疫治疗疗效。采用Kaplan-Meier法和对数秩检验估计生存概率。

结果

在我们纳入研究的192例患者中,17例发生了irAE相关AI,83例发生了其他irAE。irAE-A组和irAE-B组的DCR高于非irAE组(<0.05)。多项扩展Cox回归分析显示,irAE状态(irAE-A组与非irAE组,=0.008;irAE-B组与非irAE组,=0.020)、东部肿瘤协作组(ECOG)状态(=0.045)、肿瘤-淋巴结-转移(TNM)分期(=0.000)和治疗线数(=0.002)是PFS的独立预测因素。相反,irAE状态(irAE-A组与非irAE组,=0.009;irAE-B组与非irAE组,=0.013)、ECOG状态(=0.007)、TNM分期(=0.035)、治疗线数(=0.001)和治疗方式(=0.008)是OS的独立预测因素。

结论

irAE相关AI与癌症患者的ICI治疗疗效显著相关,这可能是一个潜在的可预测标志物。由于活性增强的T细胞对肾上腺组织的破坏,AI在一定程度上反映了T细胞活性增强。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cc1/10946443/b09981e4c09f/CMAR-16-151-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验